BeNeLuxBelgiumNetherlandsLuxembourg

Abbott bags Galapagos' first-in-class compound against rheumatoid arthritis

01.03.2012

Illinois/Mechelen – US pharma major Abbott has paid US$150m upfront to Belgian biotech firm Galapagos NV to enter into a global development and distribution partnership for its first-in-class selective oral JAK1 blocker that has recently proved effective in patients with rheumatoid arthritis (RA). Under the terms of the agreement, Abbott has secured an option to license the programme for a one-time fee of U$200m. In that case, Abbott will assume sole responsibility for Phase III clinical development and global manufacturing. Pending the achievement of certain developmental, regulatory, commercial and sales-based milestones, Galapagos would be eligible to receive additional milestone payments from Abbott, potentially amounting to US$1bn, in addition to tiered double-digit royalties on net sales upon commercialisation. Galapagos retains co-promotion rights in Belgium, the Netherlands and Luxembourg.
With the deal, Abbott enters a competition with Pfizer and Vertex, who also have JAK kinase blockers against RA under development. According to the results from an exploratory Phase II trial published last November, 83% of the 36 patients receiving GLPG0634 reached the ACR20 score and half of the treated patients went into either disease remission or low disease activity. Furthermore the compound showed no anaemia, change in blood pressure of lipids. Onno van de Stolpe, CEO of Mechelen, Belgium-based Galapagos, was also keen to emphasise the trial had demonstrated a better safety profile than other JAK inhibitors, which are in development for rheumatoid arthritis. They include two potential blockbuster DMARDS: Pfizer's tofacitinib and Vertex Inc.'s VX509, which is in Phase II.

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

BeNeLuxBelgiumNetherlandsLuxembourg

06.10.2011

Hamburg/Brussels - Evotec AG and UCB Pharma seem to be satisfied with their relationship. The Belgian pharmaceutical company entered into a second multi-year, multi-target integrated drug discovery collaboration with Evotec in...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/abbott-bags-galapagos-first-in-class-compound-against-rheumatoid-arthritis.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK73.5%
  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6174.4%
  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper